| --- | --- | |-------|-------| | | | | | | Safe Harbor | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Highlights - Vericel reported total net revenue of $124.2 million in 2020[4] - The company experienced approximately 25% revenue CAGR since the launch of MACI in 2017[4] - As of September 30, 2021, Vericel had approximately $119 million in cash and investments with no debt[8, 65] - Through Q3 2021, total revenue growth was 38%, with Epicel year-to-date revenue exceeding full-year 2020 revenue[6] Product Portfolio & Market - Vericel focuses on sports medicine and severe burn care markets with innovative cell therapies and specialty biologics[3] - The company's portfolio includes MACI for cartilage repair, Epicel for permanent skin replacement, and NexoBrid for eschar removal[3] - The addressable market for cartilage repair in the U S is over $2 billion[4, 36] - The addressable market for the burn franchise in the U S is over $200 million[60] MACI (Sports Medicine) - MACI demonstrated statistically significantly greater improvement in KOOS pain and function scores compared to microfracture at year 2[23] - Published MACI rehabilitation protocols achieve full weight-bearing in 6-8 weeks compared to 10-12 weeks for published Carticel rehabilitation protocols[35] NexoBrid & Epicel (Severe Burns) - NexoBrid is an investigational product in the U S with orphan biologic designation[49, 50] - Epicel is the only FDA-approved permanent skin replacement for adult and pediatric patients with full-thickness burns[51] - Data demonstrates lower mortality rate in Epicel patients compared to National Burn Repository[55]

Vericel Corporation (NASDAQ:VCEL) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Jeffrey Cohen - Ladenburg Thalmann Danielle Antalffy - SVB Leerink Sam Bordovsky - Truist Swayampakula Ramakanth - H.C. Wainwright Chris Cooley - Stephens Operator Ladies and gentlem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35280 VERICEL CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identif ...

VERICEL Q2 2021 RESULTS AUGUST 4, 2021 Safe Harbor 2 Vericel cautions you that all statements other than statements of historical fact included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35280 VERICEL CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificati ...

| --- | --- | |-------|---------------------------------------------------------------------------------------------------------| | | | | | Advanced Therapies for the Sports Medicine and Severe Burn Care Markets CORPORATE PRESENTATION MAY 2021 | Safe Harbor | --- | --- | --- ...

Vericel Corporation (NASDAQ:VCEL) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning & Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Kaila Krum - Truist Securities Danielle Antalffy - SVB Leerink Chris Cooley - Stephens Jeffrey Cohen - Ladenburg Thalmann Kevin DeGeeter - Oppenheimer Operator Once again thank you for stan ...

VERICEL Q1 2021 RESULTS MAY 5, 2021 Safe Harbor | --- | --- | --- ...

Financial Performance - Vericel's net revenue for Q1 2021 was $34.6 million, a 29.5% increase from $26.7 million in Q1 2020, driven by strong volume growth for MACI and Epicel[99]. - MACI generated $23.8 million in revenue for Q1 2021, up from $20.3 million in Q1 2020, reflecting a 7.4% increase[101]. - Epicel revenue increased to $9.8 million in Q1 2021 from $6.4 million in Q1 2020, representing a 53.1% growth[94]. - The net loss for Q1 2021 was $3.3 million, an improvement from a net loss of $4.7 million in Q1 2020[97]. - Gross profit for the three months ended March 31, 2021, was $22.985 million, an increase from $16.756 million in the same period in 2020, resulting in a gross profit margin of 66% compared to 63%[102][103]. Operating Expenses - Total operating expenses for Q1 2021 were $26.3 million, compared to $21.8 million in Q1 2020, indicating a 20.5% increase[98]. - Research and development costs decreased to $3.630 million for the three months ended March 31, 2021, from $3.763 million in the same period in 2020, with significant expenses allocated to MACI and Epicel[104]. - Selling, general and administrative costs rose to $22.660 million for the three months ended March 31, 2021, up from $18.069 million in the same period in 2020, primarily due to increased stock-based compensation and sales force expenses[105]. - Non-cash stock-based compensation expense increased to $7.019 million for the three months ended March 31, 2021, from $3.768 million in the same period in 2020, driven by rising stock prices[108]. Cash Flow and Investments - Cash provided by operating activities was $10.086 million for the three months ended March 31, 2021, compared to $4.686 million in the same period in 2020, reflecting improved cash collections[111]. - As of March 31, 2021, total cash and cash equivalents were $58.2 million, with short-term investments of $25.4 million and long-term investments of $26.0 million[111]. - The company generated $12.186 million from investing activities during the three months ended March 31, 2021, compared to $13.742 million in the same period in 2020[111]. - The company believes its current cash and investments will support operations for at least 12 months, although ongoing COVID-19 impacts may affect this outlook[115]. - A 1% unfavorable change in interest rates could result in a decrease of approximately $0.4 million in the fair value of the investment portfolio as of March 31, 2021[120]. Regulatory and Market Conditions - The FDA accepted the BLA for NexoBrid on September 16, 2020, with a PDUFA target date of June 29, 2021, for potential approval[90]. - The company maintains a significant safety stock of key raw materials and does not expect current supply chain interruptions to impact manufacturing operations[86]. - MACI procedures were significantly impacted by COVID-19 restrictions in early 2020, but the effects had largely dissipated by Q1 2021[82]. - Epicel procedure volumes were less affected by the pandemic, although some slowdown was observed in Q2 2020[83]. Other Income - Total other income decreased to $159,000 for the three months ended March 31, 2021, compared to $371,000 in the same period in 2020, mainly due to lower returns on investments[106].